- Business
- ScandiDos AB (publ) (SDOS.ST) develops and provides advanced measurement systems and software for quality assurance and dosimetry in modern radiation therapy for cancer treatment; its core Delta4 family includes Delta4 Phantom+ for comprehensive QA of procedures such as VMAT, RapidArc, IMRT, and Tomotherapy, Delta4 Phantom+ MR for MRI-guided radiation therapy, Delta4 HexaMotion motion platform simulating tumor movement in six dimensions, Delta4 Insight using Monte Carlo dose engine for treatment plan verification, and associated software options covering machine QA and dynamic treatments; the company also offers installation, service agreements, and customer support through subsidiaries in the US, France, and China plus approximately 40 international distributors. Founded in 2001 and headquartered in Uppsala Science Park, Sweden, ScandiDos operates globally with customers in over 50 countries, targeting radiotherapy clinics seeking precision in personalized treatments from leading equipment manufacturers. In 2024, the company completed a rights issue in April to bolster finances, achieved positive EBITDA and net income in Q2 (August-October) amid cost reductions from prior savings programs including lower personnel expenses, delivered systems to key markets like Japan, India, Spain, and Italy including Delta4 Phantom+ to Hospital Central de la Defensa Gómez Ulla in Madrid—which became a reference center in November—and Ospedale Mons. Dimiccoli in Barletta for Varian TrueBeam integration, participated in major trade shows such as ASTRO in Washington D.C., and managed inventory adjustments alongside repayments of pandemic-related tax deferrals while investing in R&D for measurement phantoms.